Novartis Earnings Beat Masks a Divergent Story: Record Sales vs. Shrinking Profits
Published on 07/23/2026 at 06:36 | Redaktion boerse-global.de
Novartis delivered a second-quarter earnings surprise on July 21 that sent analysts scrambling to revise their price targets, yet the underlying narrative remains more nuanced than the headline numbers suggest. The Swiss pharma giant reported net sales of $14.408 billion, a 3% increase that rose to just 1% on a currency-adjusted basis, while core earnings per share of $2.41 landed a full 12% above consensus estimates.
The market’s muted response tells its own story. The stock closed at €135.22 on Wednesday, barely budging 0.09% from the previous session, as investors weighed the strong quarterly performance against a full-year outlook that projects operating core income declining in the low single digits. That guidance, left unchanged from earlier this year, underscores the persistent drag from patent expirations on key drugs — even as new product momentum begins to fill the gap.
Analyst Reactions Split Between Optimism and Caution
The post-earnings analyst commentary revealed a clear divide on valuation. Bernstein Research lifted its price target from CHF 125 to CHF 132.84 on July 22, maintaining a “Market-Perform” rating as analyst Justin Smith cited modest upward revisions to adjusted EPS estimates through 2031. The DZ Bank followed suit the same day, raising its fair value from CHF 124 to CHF 130 while keeping a “Hold” recommendation; analyst Elmar Kraus pointed to the growth trajectory of newer medicines that he believes can more than offset patent losses.
JPMorgan stood as the most bullish, reaffirming “Overweight” with a CHF 135 target and arguing that further upside remains for this year’s earnings estimates. The Deutsche Bank had already weighed in before the numbers landed, reiterating “Buy” with a CHF 140 price target on July 17.
Should investors sell immediately? Or is it worth buying Novartis?
Yet UBS struck a notably more reserved tone. The Swiss bank kept its “Neutral” rating and CHF 116 target on July 22, with analyst Matthew Weston arguing that the risk-reward balance at current valuations compares unfavorably with other names in the sector. That caution echoes a broader tension: the stock has rallied 14.37% year-to-date and now trades 8.14% above its 200-day moving average of €124.99, yet the profit trajectory tells a different story.
The Profit Squeeze Behind the Rally
First-half results reveal the pressure beneath the surface. Net income fell to $6.42 billion from $7.65 billion a year earlier, while earnings per share dropped from $3.88 to $3.35. CEO Vas Narasimhan has been candid about the headwinds, publicly criticizing cost-containment measures in Germany that continue to squeeze margins in key European markets. The company’s pricing strategy in Japan, which Narasimhan has highlighted as a relative bright spot, may only partially offset the regulatory drag closer to home.
The stock’s 36.06% surge over the past twelve months has pushed market capitalization to €257.32 billion, leaving it just 6.29% below its 52-week high of €144.30 reached in late February. The relative strength index sits at a comfortable 53.2, suggesting the rally has room to run without being overextended — provided the fundamental story holds.
Pipeline Progress and Capital Returns Provide a Backstop
On the regulatory front, Novartis secured a significant win just days before the earnings release. The FDA granted full approval on July 18 for Fabhalta (iptacopan) in adults with primary IgA nephropathy, a condition where the drug can meaningfully slow kidney function decline. The approval adds a new growth vector to a pipeline that also received a boost from the early-July acquisition of UK oncology firm Myricx Bio, a deal worth up to $1.5 billion that strengthens the company’s antibody-drug conjugate platform.
Shareholders are also benefiting from the $10 billion buyback program launched in July 2025. During the first half of 2026, Novartis repurchased 13.8 million shares for $2.1 billion, leaving $5.6 billion remaining under the authorization. That capital return program provides a floor for the stock even as operational headwinds persist.
Novartis at a turning point? This analysis reveals what investors need to know now.
The Technical Line in the Sand
Chart watchers have zeroed in on the 50-day moving average of €131.90 as the key support level to watch. As long as the stock holds above that mark on a closing basis, the uptrend remains intact. A break below would open the door toward the 100-day average at €131.08, while a sustained move higher would need to clear the 52-week peak at €144.30.
The next major catalyst arrives on October 27, when Novartis reports third-quarter and nine-month results. The company’s “Meet Novartis Management” investor conference follows on November 18 in London. Until then, the market appears content to let the tug-of-war between strong quarterly execution and a cautious full-year outlook play out — with implied volatility at a moderate 23.73% suggesting no one is betting on a sudden resolution.
Ad
Novartis Stock: New Analysis - 23 July
Fresh Novartis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
